## CQ-12: Health Emergencies Clinical Trial Landscape 2026

**Question**: What are the key health emergencies or emerging health priorities that multiple clinical trials are targeting right now?
**Date**: 2026-02-01
**Status**: VALIDATED
**group_id**: `cq12-health-emergencies-2026`

### Key Entities

| Entity | CURIE | Type | Role |
|--------|-------|------|------|
| Cancer/Immunotherapy | Category | Health Priority | CAR-T, checkpoint inhibitors |
| Metabolic Disorders/GLP-1 | Category | Health Priority | Obesity, diabetes, mental health |
| Neurodegenerative Disease | Category | Health Priority | Anti-amyloid, neuromodulation |
| Antimicrobial Resistance | Category | Health Priority | Novel antibiotics, FMT |

### Key Findings

- **Cancer/Immunotherapy**: CAR-T cell therapy expanding beyond hematologic malignancies to autoimmune diseases (Graves' disease); checkpoint inhibitor combinations with chemotherapy
- **Metabolic Disorders (GLP-1)**: GLP-1 agonists being repurposed for mental health applications including depression and alcohol use disorder in addition to obesity/diabetes
- **Neurodegenerative Disease**: Anti-amyloid therapies (LEQEMBI), neuromodulation techniques (rTMS, deep brain stimulation), biomarker development
- **Antimicrobial Resistance (AMR)**: FMT for decolonization of carbapenem-resistant Enterobacteriaceae, optimized antibiotic duration protocols

### Graph Summary

- **Nodes**: 4 health priority categories
- **Edges**: 11 sample clinical trials

### Provenance

| Source | Tools Used | Evidence |
|--------|------------|----------|
| ClinicalTrials.gov | curl API (query.intr, query.cond, filter.overallStatus) | Recruiting trials |

### Sample Clinical Trials

**Cancer/Immunotherapy:**
| NCT ID | Title | Phase |
|--------|-------|-------|
| NCT:06463861 | Sequential CD19 CARNK and CAR-T in B Cell Lymphoma | Phase 1 |
| NCT:07288879 | DALY II Japan/MB-CART2019.1 for DLBCL | Phase 2 |
| NCT:04807673 | Pembrolizumab + Chemo vs CRT for ESCC | Phase 3 |

**Metabolic Disorders/GLP-1:**
| NCT ID | Title | Phase |
|--------|-------|-------|
| NCT:06437146 | Liraglutide for Obesity in HIV | Phase 4 |
| NCT:06939088 | Tirzepatide for Alcohol Use in Schizophrenia | Phase 2 |
| NCT:07136714 | Semaglutide for Depression with Obesity | Phase 4 |

**Neurodegenerative Disease:**
| NCT ID | Title | Phase |
|--------|-------|-------|
| NCT:07324161 | Transcranial Magnetic Stimulation for Alzheimer's | N/A |
| NCT:04396873 | PET Imaging of Cyclooxygenases in Neurodegeneration | Phase 1 |
| NCT:06399368 | LEQEMBI Effect on Cerebral and Retinal Amyloid | Observational |

**Antimicrobial Resistance:**
| NCT ID | Title | Phase |
|--------|-------|-------|
| NCT:05791396 | FMT to Eradicate Carbapenem-resistant Enterobacteriaceae | Phase 1 |
| NCT:05903352 | Customized Antibiotic Duration for CAP | Phase 3 |

### Emerging Trends

- **CAR-T Expansion**: Beyond hematologic malignancies to autoimmune diseases (Graves' disease)
- **GLP-1 Repurposing**: Mental health applications (depression, alcohol use disorder)
- **AI Integration**: Biomarker discovery and personalized treatment selection
- **Combination Therapy**: Multi-modal approaches (chemo + immunotherapy + targeted)

### Therapeutic Modalities

| Type | Examples |
|------|----------|
| Cell Therapy | CAR-T, CAR-NK, TILs |
| Biologics | Checkpoint inhibitors, Anti-amyloid antibodies, GLP-1 agonists |
| Neuromodulation | rTMS, Deep brain stimulation |
| Microbiome | FMT, Phage therapy |
